Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Feb;37(2):246–250. doi: 10.1128/aac.37.2.246

Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins.

K M Wasan 1, G A Brazeau 1, A Keyhani 1, A C Hayman 1, G Lopez-Berestein 1
PMCID: PMC187647  PMID: 8452354

Abstract

The role of liposome composition and temperature in the distribution of amphotericin B (AmB) with serum lipoproteins and the role of particle charge in AmB transfer to serum lipoproteins were determined. Serum obtained from healthy volunteers was incubated with known concentrations of AmB or different liposomal formulations of AmB (1 to 100 micrograms/ml) at 37 degrees C for various time intervals (5, 10, 20, 30, 45, and 60 min). After each interval, serum was removed and separated into high-density lipoprotein (HDL) and low-density lipoprotein (LDL) fractions by an LDL-direct assay. The distribution of AmB (Fungizone) at 5 min through 1 h of incubation at 25 degrees C remained constant and was similar in the HDL and LDL fractions. At 37 degrees C, at 5 through 45 min of incubation, 54 to 61% of AmB was recovered in the HDL fraction; however, at 1 h more than 75% of the AmB concentration was recovered in the HDL fraction. In contrast, 87.5 to 92% AmB was recovered in the HDL fraction throughout the incubation when negatively charged liposomal AmB (dimyristoylphosphatidylcholine [DMPC]:dimyristoylphosphatidylglycerol [DMPG], 7:3 [wt/wt]) was used. With positively charged liposomes, 75 to 87.7% of AmB was recovered in the HDL fraction through the different time points studied. AmB incorporated into DMPC (neutral) and DMPG (negative) liposomes, and AmB was distributed in an HDL:LDL ratio of 6:4 following 1 h of incubation. Ninety percent of AmB and 80% of the lipid were found in the HDL fraction in a 3:1 molar DMPG:AmB ratio and in the LDL fraction in a 6:1 molar ratio. Lipid charge and temperature play a role in AmB distribution into serum lipoproteins. AmB and DMPG may contransfer as an intact drug-lipid complex to serum lipoproteins.

Full text

PDF
246

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreoli T. E. On the anatomy of amphotericin B-cholesterol pores in lipid bilayer membranes. Kidney Int. 1973 Nov;4(5):337–345. doi: 10.1038/ki.1973.126. [DOI] [PubMed] [Google Scholar]
  2. Atkinson A. J., Jr, Bennett J. E. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother. 1978 Feb;13(2):271–276. doi: 10.1128/aac.13.2.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Babiak J., Rudel L. L. Lipoproteins and atherosclerosis. Baillieres Clin Endocrinol Metab. 1987 Aug;1(3):515–550. doi: 10.1016/s0950-351x(87)80022-8. [DOI] [PubMed] [Google Scholar]
  4. Barwicz J., Gareau R., Audet A., Morisset A., Villiard J., Gruda I. Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems. Biochem Biophys Res Commun. 1991 Dec 16;181(2):722–728. doi: 10.1016/0006-291x(91)91250-g. [DOI] [PubMed] [Google Scholar]
  5. Bentzen C. L., Acuff K. J., Marechal B., Rosenthal M. A., Volk M. E. Direct determination of lipoprotein cholesterol distribution with micro-scale affinity chromatography columns. Clin Chem. 1982 Jul;28(7):1451–1456. [PubMed] [Google Scholar]
  6. Brajtburg J., Elberg S., Bolard J., Kobayashi G. S., Levy R. A., Ostlund R. E., Jr, Schlessinger D., Medoff G. Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis. 1984 Jun;149(6):986–997. doi: 10.1093/infdis/149.6.986. [DOI] [PubMed] [Google Scholar]
  7. Chabot G. G., Pazdur R., Valeriote F. A., Baker L. H. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci. 1989 Apr;78(4):307–310. doi: 10.1002/jps.2600780409. [DOI] [PubMed] [Google Scholar]
  8. Christiansen K. J., Bernard E. M., Gold J. W., Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985 Nov;152(5):1037–1043. doi: 10.1093/infdis/152.5.1037. [DOI] [PubMed] [Google Scholar]
  9. Cushley R. J., Treleaven W. D., Parmar Y. I., Chana R. S., Fenske D. B. Surface diffusion in human serum lipoproteins. Biochem Biophys Res Commun. 1987 Aug 14;146(3):1139–1145. doi: 10.1016/0006-291x(87)90766-2. [DOI] [PubMed] [Google Scholar]
  10. Kim H., Loebenberg D., Marco A., Symchowicz S., Lin C. Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother. 1984 Oct;26(4):446–449. doi: 10.1128/aac.26.4.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Koldin M. H., Kobayashi G. S., Brajtburg J., Medoff G. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob Agents Chemother. 1985 Jul;28(1):144–145. doi: 10.1128/aac.28.1.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lopez-Berestein G., Kasi L., Rosenblum M. G., Haynie T., Jahns M., Glenn H., Mehta R., Mavligit G. M., Hersh E. M. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res. 1984 Jan;44(1):375–378. [PubMed] [Google Scholar]
  13. Lopez-Berestein G. Liposomes as carriers of antifungal drugs. Ann N Y Acad Sci. 1988;544:590–597. doi: 10.1111/j.1749-6632.1988.tb40459.x. [DOI] [PubMed] [Google Scholar]
  14. Lopez-Berestein G., Mehta R., Hopfer R. L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945. doi: 10.1093/infdis/147.5.939. [DOI] [PubMed] [Google Scholar]
  15. Lopez-Berestein G., Rosenblum M. G., Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1984 Summer;1(3):199–205. doi: 10.1089/cdd.1984.1.199. [DOI] [PubMed] [Google Scholar]
  16. Morton R. E. Interaction of lipid transfer protein with plasma lipoproteins and cell membranes. Experientia. 1990 Jun 15;46(6):552–560. doi: 10.1007/BF01939693. [DOI] [PubMed] [Google Scholar]
  17. Patterson T. F., Andriole V. T. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol. 1989;25 (Suppl 2):S63–S68. [PubMed] [Google Scholar]
  18. Perez-Soler R., Khokhar A. R., Hacker M. P., Lopez-Berestein G. Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles. Cancer Res. 1986 Dec;46(12 Pt 1):6269–6273. [PubMed] [Google Scholar]
  19. Surewicz W. K., Epand R. M., Pownall H. J., Hui S. W. Human apolipoprotein A-I forms thermally stable complexes with anionic but not with zwitterionic phospholipids. J Biol Chem. 1986 Dec 5;261(34):16191–16197. [PubMed] [Google Scholar]
  20. Tolins J. P., Raij L. Adverse effect of amphotericin B administration on renal hemodynamics in the rat. Neurohumoral mechanisms and influence of calcium channel blockade. J Pharmacol Exp Ther. 1988 May;245(2):594–599. [PubMed] [Google Scholar]
  21. Wasan K. M., Vadiei K., Lopez-Berestein G., Luke D. R. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis. 1990 Mar;161(3):562–566. doi: 10.1093/infdis/161.3.562. [DOI] [PubMed] [Google Scholar]
  22. Whitaker C. F., Srinivasan S. R., Berenson G. S. Simplified methods for measuring cholesterol concentrations of high-density lipoprotein subclasses in serum compared. Clin Chem. 1986 Jul;32(7):1274–1278. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES